{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:12:24Z","timestamp":1774368744901,"version":"3.50.1"},"reference-count":32,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz J Med Biol Res"],"DOI":"10.1590\/1414-431x2024e13392","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T11:24:47Z","timestamp":1722252287000},"source":"Crossref","is-referenced-by-count":3,"title":["A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.1590","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-5474","authenticated-orcid":false,"given":"Shichao","family":"Cui","sequence":"first","affiliation":[{"name":"Guangdong Provincial Reproductive Science Institute (Guangdong Provincial Fertility Hospital),  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0623-8136","authenticated-orcid":false,"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Reproductive Science Institute (Guangdong Provincial Fertility Hospital),  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7527-5920","authenticated-orcid":false,"given":"Wensheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Reproductive Science Institute (Guangdong Provincial Fertility Hospital),  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8165-3315","authenticated-orcid":false,"given":"Bin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Xiamen Health and Medical Big Data Center,  China; Xiamen Medicine Research Institute,  China; Xiamen Key Laboratory of Natural Medicine Research and Development,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4256-1001","authenticated-orcid":false,"given":"Xingming","family":"Zhong","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Reproductive Science Institute (Guangdong Provincial Fertility Hospital),  China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref1","first-page":"7","article-title":"Cyclosporin a: a new era in organ transplantation","volume":"10","author":"DeBakey ME","year":"1984","journal-title":"Compr Ther"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1016\/S0039-6257(00)00205-8","article-title":"The treatment of dry eye","volume":"45","author":"Calonge M","year":"2001","journal-title":"Surv Ophthalmol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e16710","DOI":"10.1097\/MD.0000000000016710","article-title":"Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: a 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study","volume":"98","author":"Chen D","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"ref4","first-page":"CD10051","article-title":"Topical cyclosporine A therapy for dry eye syndrome","volume":"9","author":"de Paiva CS","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4049\/jimmunol.128.1.355","article-title":"Effect of cyclosporin A on human lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF","volume":"128","author":"Hess AD","year":"1982","journal-title":"J Immunol"},{"key":"ref6","first-page":"131","article-title":"Cyclosporin A inhibits induction of IL-2 receptor alpha chain expression by affecting activation of NF-kB-like factor(s) in cultured human T lymphocytes","volume":"1","author":"Brini AT","year":"1990","journal-title":"Eur Cytokine Netw"},{"key":"ref7","series-title":"Compendium of Pharmaceuticals and Specialities. The Canadian Drug Reference for Health Professionals","year":"2005","edition":"2005 ed"},{"key":"ref8","first-page":"CD7893","article-title":"Effect of cyclosporine on blood pressure","author":"Robert N","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/lt.25071","article-title":"Pregnancy outcomes following single and repeat liver transplantation: an international 2-center cohort","volume":"24","author":"Zaffar N","year":"2018","journal-title":"Liver Transpl"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00535-010-0273-x","article-title":"Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis","volume":"45","author":"Kobayashi T","year":"2010","journal-title":"J Gastroenterol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/00365521.2013.848231","article-title":"Long-term increase in serum cholesterol levels in ulcerative colitis patients treated with cyclosporine: an underdiagnosed side effect frequently associated with other drug-related complications","volume":"49","author":"B\u00e1lint A","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/healthcare10030420","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel MA","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/00002018-200326030-00002","article-title":"Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA)","volume":"26","author":"Brown EG","year":"2003","journal-title":"Drug Saf"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2165\/00002018-200225060-00009","article-title":"Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART","volume":"25","author":"Brown EG","year":"2002","journal-title":"Drug Saf"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans SJ","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1111\/bcp.15802","article-title":"Considerations on the use of different comparators in pharmacovigilance: a methodological review","volume":"89","author":"Gravel CA","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00041552-199212000-00008","article-title":"Recent advances in the mechanism of action of cyclosporine and FK506","volume":"1","author":"Tocci MJ","year":"1992","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.3262237","article-title":"Effects of cyclosporine A on T cell development and clonal deletion","volume":"241","author":"Jenkins MK","year":"1988","journal-title":"Science"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"19039","DOI":"10.1002\/jcp.28543","article-title":"Cyclosporine A improves pregnancy outcomes in women with recurrent pregnancy loss and elevated Th1\/Th2 ratio","volume":"234","author":"Azizi R","year":"2019","journal-title":"J Cell Physiol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1142723","DOI":"10.3389\/fimmu.2023.1142723","article-title":"Sex and gender influence on immunity and autoimmunity","volume":"14","author":"Lahita RG","year":"2023","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13071-020-3958-x","article-title":"Evaluation of in vitro antileishmanial efficacy of cyclosporin A and its non-immunosuppressive derivative, dihydrocyclosporin A","volume":"13","author":"Zheng ZW","year":"2020","journal-title":"Parasit Vectors"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3892\/etm.2020.9469","article-title":"Th17\/Treg-cell balance in the peripheral blood of pregnant females with a history of recurrent spontaneous abortion receiving progesterone or cyclosporine A","volume":"21","author":"Wang S","year":"2021","journal-title":"Exp Ther Med"},{"key":"ref23","first-page":"1379","article-title":"Cyclosporine A improves adhesion and invasion of mouse preimplantation embryos via upregulating integrin beta3 and matrix metalloproteinase-9","volume":"7","author":"Huang YH","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12958-020-00658-0","article-title":"Cyclosporin A protects JEG-3 cells against oxidative stress-induced apoptosis by inhibiting the p53 and JNK\/p38 signaling pathways","volume":"18","author":"He B","year":"2020","journal-title":"Reprod Biol Endocrinol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1186\/s13063-020-04716-1","article-title":"A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for LIving FEtuses (ILIFE) trial","volume":"21","author":"Yang S","year":"2020","journal-title":"Trials"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1080\/01443615.2022.2141615","article-title":"The effect of hydroxychloroquine on pregnancy outcomes in patients with unexplained recurrent pregnancy loss: a placebo-controlled study \u201cpilot study\u201d","volume":"42","author":"Moini A","year":"2022","journal-title":"J Obstet Gynaecol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/aji.12493","article-title":"Unexplained recurrent miscarriage and recurrent implantation failure: is there a place for immunomodulation?","volume":"76","author":"Mekinian A","year":"2016","journal-title":"Am J Reprod Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pds.4944","article-title":"Quality evaluation of the Japanese Adverse Drug Event Report database (JADER)","volume":"29","author":"Tsuchiya M","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15200","article-title":"Evaluation of patient reporting of adverse drug reactions to the UK \u2018Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys","volume":"15","author":"Avery AJ","year":"2011","journal-title":"Health Technol Assess"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40264-018-0647-1","article-title":"EudraVigilance medicines safety database: publicly accessible data for research and public health protection","volume":"41","author":"Postigo R","year":"2018","journal-title":"Drug Saf"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7547\/87507315-84-1-35","article-title":"Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems","volume":"84","author":"Kessler DA","year":"1994","journal-title":"J Am Podiatr Med Assoc"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro TT","year":"2015","journal-title":"Vaccine"}],"container-title":["Brazilian Journal of Medical and Biological Research"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0100-879X2024000100658&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T11:25:04Z","timestamp":1722252304000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0100-879X2024000100658&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":32,"alternative-id":["S0100-879X2024000100658"],"URL":"https:\/\/doi.org\/10.1590\/1414-431x2024e13392","relation":{},"ISSN":["1414-431X","0100-879X"],"issn-type":[{"value":"1414-431X","type":"electronic"},{"value":"0100-879X","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e13392"}}